AM is a consultant to Personalis Inc. AB is a founder and consultant to Personalis, Inc. Stanford University holds the intellectual property on any genotypic risk assessment technologies described in the paper that may be licensed to various companies.
Stanford University holds the intellectual property on genotypic risk assessment technologies described in the manuscript that may be licensed to various companies, but the data visualization strategies presented in Figure 3 and Additional File 6 are not intellectual property of Personalis, Inc.
Currently, he's making investment in data analytics and risk assessment technology.
The limitations of risk assessment technology can be lost through approaches that rely heavily on quantitative PRA results (referred to as risk measures in this paper), because of the unambiguous but potentially misleading message that can be delivered by risk-based numbers.
The integration of a new risk assessment technology into clinical practice can be accompanied by several challenges.
Specific lessons were drawn for international rule-making for health equity, and emphasis was given to biotechnology, risks assessment, technology transfer, sharing benefits of global scientific and technological advances, and technical cooperation.
Twenty-first century teams need expertise in forecast modeling, adaptation, health and environmental risk assessment, control technologies, and of course the decision and social sciences in developing prevention or intervention strategies.
It then provided the suppliers with self-assessment and reporting tools, and applied risk assessment analysis technology.
In contrast, risk assessment procedures take technologies for granted, non-technical expertise is not considered relevant and sociopolitical analyses about technology implementation are addressed as a problem per se.
Slovic argues that three things stand in the way of a logical, analytical risk assessment of new technologies: our level of dread, our degree of familiarity (or lack thereof), and the number of people we believe the technology will affect.
So, following my heart, I transferred to Humboldt University in Berlin and started a research project on risk assessment in gene technology.
